Table 3.
Hospital events and mortality among patients with PE
| Study | Hospital events | Mortality | |||
|---|---|---|---|---|---|
| Event | Patients with PE | Patients without PE | Patients with PE | Patients without PE | |
| Benito et al. (2020) (Spain) 13 | ICU admission | 15/32 (47%) | 10/44 (23%); p = 0.027 | 3/32 (9%) | 5/44 (11%) |
| MV | 14/32 (44%) | 8/44 (18%); p = 0.015 | ‐ | ‐ | |
| Hospital stay, median (IQR) | 15.5 (9.8) days | 7 (11) days; p = 0.010 | ‐ | ‐ | |
| Bilaloglu et al. (2020) (USA) 15 | ‐ | ‐ | ‐ | Ward, 7/54 (13%) | Ward, 282/2216 (12.7%) |
| ‐ | ‐ | ‐ | ICU, 33/52 (63%) | ICU, 305/585 (52.1%)a | |
| COVID‐ICU group (2021) (France, Belgium, and Switzerland) 17 | ‐ | ‐ | ‐ | 135/350 (38.6%)b | 1163/3874 (30.0%)b |
| Fang et al. (2020) (UK) 20 | ‐ | 6/41 (15%) | 5/52 (10%)c | ‐ | ‐ |
| Fauvel et al. (2020) (France) 21 | ICU admission | 32/103 (31.1%) | 153/1137 (13.5%); p < 0.001 | 9/103 (8.7%) | 142/1137 (12.5%) |
| MV | 25/103 (24.3%) | 83/1137 (7.3%); p < 0.001 | ‐ | ‐ | |
| Gonzalez‐Fajardo et al. (2021) (Spain) 23 | ‐ | ‐ | ‐ | 7/58 (12%) | ‐ |
| Gupta et al. (2020) (USA) 24 | ‐ | ‐ | ‐ | 19/51 (37%) | ‐ |
| Monfardini et al. (2020) (Italy) 27 | ‐ | ‐ | ‐ | 10/26 (38%) | ‐ |
| Nordberg et al. (2021) (Sweden) 28 | ‐ | ‐ | ‐ | 10/41 (24%) | ‐ |
| Planquette et al. (2021) (France) 29 | MV | 25/59 (42.4%) | 25/118 (21.2%) | 12/59 (20.3%) | 19/118 (16.1%)c |
| Hospital stay, median (IQR)d | 12 (3–18) days | 8 (2–15) daysc | ‐ | ‐ | |
Abbreviations: ICU, intensive care unit; IQR, interquartile range; MV, mechanical ventilation; PE, pulmonary embolism; SD, standard deviation.
a
Patients with no thrombotic events.
b
At Day 90; calculated; study reports PE to be significantly more common in patients who had died after 90 days than in those who were alive (10.4% vs. 7.3%; p < 0.001).
c
Patients who underwent CTPA.
d
IQR reported as width of range. p values are shown where statistically significant differences are reported.